Torrent Pharmaceuticals Ltd Q1 FY25 Earnings Call Analysis

- India business: Expecting low teens growth going forward, with Q1 at 15%, driven by 2.5% volume, 8.5% price, and 4% new products. Chronic segment growth remains sustainable (~13%+). - Cardiac portfolio: Losar brand expected to slip to #3 next year; growth driven by 4-5 other strong cardiac brands in future growth markets. No significant new cardiac launches anticipated soon; growth from existing brands. - US business: Targeting 5-10 product approvals this year, including oncology and diversified therapies; profitability expected post-R&D over next 2-3 years as launches ramp up. - Brazil: Underlying growth rate of 12-13% (constant currency), with 3-6 product launches annually and 19 molecules pending approval. - Germany: Mid-to-high single digits growth expected, driven by winning new tenders. - Consumer health: Key brands like Shelcal growing high teens; overall consumer segment growth supported by sustained A&P spend. Overall, growth driven by portfolio derisking, new launches, market share gains, and expansion in key regions.

- The company continues to pursue acquisitions as an integral part of its growth strategy, focusing on creating long-term shareholder value. - Acquisition formats include business transfers through slump sales and company acquisitions (e.g., Curatio was a recent company acquisition). - All combinations for acquisitions are open, with a preference for acquiring 100% stakes. - Interest lies in both branded assets and good generic assets. - Focus is on existing markets like Brazil, Mexico, and potentially new markets. - No specific inorganic investment figures or timelines were provided. - R&D spend is steady at around 5% of revenues, with no material change expected for the full year. - Capital allocation is expected to be tied to cash flow and EBITDA generation, with FY'26 anticipated to be net cash positive. (Source: Pages 5, 6, 7, 8, 12, and 13)